Ovoca Gold (GB:OVB) has released an update.
Ovoca Bio, a biopharmaceutical company specializing in women’s health, published its 2023 Annual Report, revealing the discontinuation of its lead product Orenetide’s development after a Phase II study showed no benefit. The company also addressed the disposal of its Russian assets amidst sanctions and is actively seeking strategic opportunities to optimize its corporate structure and stabilize financially. The full report is available on Ovoca Bio’s website, marking a pivotal moment for reassessing the firm’s strategic direction.
For further insights into GB:OVB stock, check out TipRanks’ Stock Analysis page.
